START WITH YOUR QUESTION
Explore the evidence by outcome
Find what has been assessed, who or what was studied, and the limits of the finding.
This finder uses the same selected-source assessments as the peptide and stack guides. Evidence types describe the underlying source research, which may be indirect for the requested outcome. Filters select existing assessments; they do not recalculate grades or establish treatment recommendations. Topics without an outcome assessment remain in the peptide directory.
32 assessments match these filters. Showing 20 on page 1 of 2.
Collagen peptides · Peptide assessment
Activity-related joint pain
Human research
- Population / model
- 147 athletes recruited; 97 analyzed
- Formulation / route
- Oral collagen hydrolysate
- Study design
- Randomized double-blind placebo-controlled trial
Oral collagen hydrolysate may improve some measures of activity-related joint discomfort, but the evidence is less decisive than marketing often suggests.[1] A 24-week randomized trial recruited 147 athletes and analyzed 97; several pain measures favored collagen over placebo.[1] The missing participants, multiple outcomes, and specific athletic population limit confidence and generalizability.[1]
Main limitation: Attrition, multiple outcomes, and limited population applicability.[1]
BPC-157 · Peptide assessment
Added benefit of a peptide combination
Human and preclinical research
- Population / model
- 4 human combination recipients; rats with repaired Achilles tendons
- Formulation / route
- Study-specific; no cross-route equivalence assumed
- Study design
- Small nonrandom human subgroup and randomized exploratory rat study
The knee case series included only four recipients of BPC-157 plus thymosin beta-4 and did not randomize treatment.[2] A rat Achilles study found no additional benefit from its BPC-157/TB-500 combination over monotherapy, with small endpoint samples.[3] Neither study establishes the benefit or safety of commercial peptide blends in people.[2][3]
Main limitation: Formulation and route cannot be generalized.[2][3]
GLOW stack · Stack assessment
Additional recovery benefit from GHK-Cu
Animal or cell research
- Population / model
- Rats after Achilles tendon surgery
- Formulation / route
- BPC-157 / TB-500; no GHK-Cu group
- Study design
- Indirect animal combination research
The experiment did not test the three-component combination.[3]
Main limitation: A missing treatment group cannot establish an added effect.[3]
Wolverine stack · Stack assessment
Additional tendon-healing benefit
Animal or cell research
- Population / model
- 32 rats; four tendons per group for each endpoint type
- Formulation / route
- Experimental BPC-157 / TB-500 combination
- Study design
- Controlled rat experiment
No additional benefit was demonstrated for the combination in this model.[3]
Main limitation: An early surgical rat model cannot establish clinical recovery in people.[3]
Wolverine stack · Stack assessment
Better knee-pain relief from the combination
Human research
- Population / model
- Four combination recipients within a knee-pain case series
- Formulation / route
- Intra-articular BPC-157 with thymosin beta-4
- Study design
- Uncontrolled human case series
The small, nonrandomized subgroup cannot establish an added treatment effect.[2]
Main limitation: The studied preparation cannot be assumed equivalent to a commercial TB-500 blend.[2]
BPC-157 · Peptide assessment
Circulating growth hormone in humans
Animal or cell research
- Population / model
- Cultured rat tendon fibroblasts
- Formulation / route
- Study-specific; no cross-route equivalence assumed
- Study design
- Controlled in vitro receptor-expression experiment
A cell-culture study found increased growth-hormone receptor expression in rat tendon fibroblasts.[4] That is different from demonstrating increased circulating growth hormone, and it does not validate combining BPC-157 with growth-hormone secretagogues in people.[4] Receptors describe how a cell may respond to a hormone; this experiment did not measure a rise in blood growth-hormone levels or test a clinical benefit from raising those levels.[4]
Main limitation: Receptor expression is not systemic hormone concentration.[4]
Tirzepatide · Peptide assessment
Comparative weight reduction over 72 weeks
Human research
- Population / model
- 751 adults with obesity without diabetes
- Formulation / route
- Subcutaneous trial formulations and maximum tolerated regimens
- Study design
- Open-label randomized head-to-head trial
In the 2025 SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight reduction than semaglutide in adults with obesity without diabetes.[5] Among 751 randomized participants, mean weight change at 72 weeks was −20.2% with tirzepatide and −13.7% with semaglutide, using the maximum tolerated trial regimens.[5] The trial was open-label and manufacturer funded, which should be considered alongside its direct randomized comparison.[5]
Main limitation: Open-label, manufacturer-funded, specific regimens and population.[5]
BPC-157 · Peptide assessment
Human digestive benefit
Animal or cell research
- Population / model
- Rat gastric-injury models; separate human ulcerative-colitis abstract
- Formulation / route
- Study-specific; no cross-route equivalence assumed
- Study design
- Rat injury experiments; regulatory assessment of an abstract-only human trial
Studies in animals report reduced injury in rat models of gastric ulcers and concentrated-alcohol exposure.[6][7] FDA separately reviewed a small placebo-controlled ulcerative-colitis study reported only as a meeting abstract, with insufficient detail for a reliable effectiveness assessment.[8] Those findings do not establish a benefit for commercial oral BPC-157 products or nonspecific “leaky gut” symptoms.[6][8]
Main limitation: Human evidence includes an incompletely reported meeting abstract, with insufficient detail to assess effectiveness reliably.[6][7][8]
KLOW stack · Stack assessment
Human intestinal benefit from KLOW
Animal or cell research
- Population / model
- Intestinal / immune cells and mice with experimental colitis
- Formulation / route
- KPV alone; oral administration in mice
- Study design
- Indirect cell and animal experiments
The study does not test the KLOW combination in humans.[9]
Main limitation: Experimental inflammatory outcomes are not established clinical benefits of a four-peptide blend.[9]
BPC-157 · Peptide assessment
Human pharmacokinetics
Human and preclinical research
- Population / model
- Rats and dogs;2human safety participants
- Formulation / route
- Study-specific; no cross-route equivalence assumed
- Study design
- Animal LC-MS/MS pharmacokinetics; human safety pilot without PK assays
The pharmacokinetic paper reported mean intact-peptide half-lives below thirty minutes in tested rat and dog regimens.[10] The two-person human intravenous paper measured clinical laboratory markers rather than BPC-157 concentrations.[11] These studies therefore do not establish a human half-life or dosing frequency.[10][11]
Main limitation: Intact peptide must be distinguished from total radiolabel.[10][11]
BPC-157 · Peptide assessment
Human safety
Human research
- Population / model
- Two previously exposed adults; broader clinical-note cohort
- Formulation / route
- Study-specific; no cross-route equivalence assumed
- Study design
- Two-person safety pilot; uncontrolled EHR preprint
The two-person intravenous pilot reported no adverse effects during three days of monitoring, but both participants had previous exposure.[11] This small, selected sample cannot establish routine or long-term safety.[11] The clinical-note preprint also describes neuropsychiatric, skin or injection-site, and gastrointestinal symptoms, without establishing causation or reliable event rates.[12]
Main limitation: Brief monitoring and nonstandard adverse-event ascertainment.[11][12]
GHK-Cu · Peptide assessment
Injected versus topical skin benefit
Evidence type not classified
- Population / model
- No matched human comparison identified
- Formulation / route
- Systemic injection versus topical application
- Study design
- No direct comparative human study identified
Clinical superiority of injected GHK-Cu over topical GHK-Cu has not been demonstrated in the human evidence reviewed here.[13][14] A topical study cannot establish the effectiveness or safety of systemic injection, because exposure and delivery are different.[13] FDA identifies limited human safety data for injectable GHK-Cu and potential immunogenicity associated with aggregation and peptide impurities.[14]
Main limitation: A delivery hypothesis does not establish benefit or safety.[13][14]
TB-500 · Peptide assessment
Injury healing with the TB-500 fragment
Evidence type not classified
- Population / model
- Ophthalmic trials do not represent musculoskeletal-injury treatment
- Formulation / route
- Marketed injectable fragment versus researched ophthalmic full-length peptide
- Study design
- No direct human fragment evidence; indirect full-length ophthalmic trial
The name TB-500 requires clarification before interpreting any study.[14] FDA describes TB-500 as the thymosin beta-4 fragment LKKTETQ and reports that it has not identified human exposure data for that fragment.[14] Full-length thymosin beta-4 has been studied in humans, including investigational eye drops for corneal disease, but that is a different molecule, formulation, target tissue, and route.[15]
Main limitation: Molecular identity and route prevent extrapolation.[14][15]
BPC-157 · Peptide assessment
Interstitial-cystitis symptoms
Human research
- Population / model
- 12 women with interstitial cystitis
- Formulation / route
- Study-specific; no cross-route equivalence assumed
- Study design
- Uncontrolled retrospective case series
An uncontrolled retrospective report described twelve women treated by cystoscopic bladder injection; ten reported complete symptom resolution and two partial improvement.[16] The paper describes follow-up timing inconsistently, and the lack of a comparator prevents attributing improvement to BPC-157.[16] This procedure-specific report does not establish that oral or subcutaneous products treat bladder pain.[16]
Main limitation: No comparator; inconsistent timing; route-specific procedure.[16]
BPC-157 · Peptide assessment
Knee-pain symptom relief
Human research
- Population / model
- 16 contacted patients,12 receiving BPC-157 alone
- Formulation / route
- Study-specific; no cross-route equivalence assumed
- Study design
- Uncontrolled retrospective case series
Of seventeen patients identified, sixteen were contacted; eleven of twelve receiving BPC-157 alone reported improvement.[2] The uncontrolled, retrospective design and subjective outcomes cannot separate a drug effect from recovery, expectation or other care.[2] The patients had different types of knee pain, and the study did not include a comparable group receiving placebo or usual care alone.[2]
Main limitation: No placebo or objective repair endpoint.[2]
CJC-1295 + ipamorelin · Stack assessment
Long-term safety of the combination
Context sources
- Population / model
- Limited clinical safety information
- Formulation / route
- CJC-1295 and ipamorelin products
- Study design
- Regulatory safety assessment
Available safety information does not validate long-term use of the combination.[14]
Main limitation: Regulatory concerns cannot be converted into a reliable event rate for the pair.[14]
BPC-157 · Peptide assessment
Muscle recovery in people
Animal or cell research
- Population / model
- Rats with induced muscle injuries
- Formulation / route
- Study-specific; no cross-route equivalence assumed
- Study design
- Controlled rat surgical and crush-injury experiments
Rat experiments reported improved muscle-to-bone reattachment and recovery after muscle–tendon junction separation.[17][18] A separate rat muscle-crush experiment reported improved healing during corticosteroid exposure.[19] These induced injuries support further research but do not establish human recovery times, effective doses or safe drug combinations.[17][18][19]
Main limitation: No direct human muscle-recovery trial in these studies.[17][18][19]
BPC-157 · Peptide assessment
Oral versus injected effectiveness
Animal or cell research
- Population / model
- Rats and dogs
- Formulation / route
- Study-specific; no cross-route equivalence assumed
- Study design
- Animal route-specific experiments; no human head-to-head comparison in these sources
Oral administration produced effects in some rat injury experiments, but those experiments did not measure clinical equivalence in humans.[6][17] A pharmacokinetic study examined intravenous and intramuscular administration in rats and dogs; it did not evaluate human oral absorption.[10] These sources do not establish that capsules and injections are interchangeable.[10][17]
Main limitation: Animal responses are not human bioavailability.[6][10][17]
Semaglutide · Peptide assessment
Quality assurance of no-prescription online products
Product-testing research
- Population / model
- Three delivered products from six selected online orders
- Formulation / route
- Products sold for injection
- Study design
- Small observational test-purchase and laboratory study
A purity percentage does not establish correct identity, labeled amount, sterility, endotoxin control, or clinical safety.[20] In a 2024 test-purchase study of no-prescription online semaglutide, only three of six orders arrived.[20] The delivered samples contained more semaglutide than labeled, had reported purity far below the advertised 99%, and one contained elevated endotoxin despite no viable microorganisms being detected.[20]
Main limitation: Documents failures; does not estimate market-wide prevalence.[20]
CJC-1295 · Peptide assessment
Recovery or muscle-performance benefit
Human research
- Population / model
- Healthy adults followed for 28 or 49 days
- Formulation / route
- Subcutaneous long-acting CJC-1295 in the cited trials
- Study design
- Randomized pharmacology trials; indirect for clinical benefit
CJC-1295 has demonstrated hormonal activity in humans, but that does not establish improved recovery or muscle performance.[21] Two short randomized, placebo-controlled trials of the long-acting formulation found increases in growth hormone and IGF-1 in healthy adults.[21] These were pharmacology studies, not demonstrations of faster injury healing, greater strength, better sleep, or longer life.[21]
Main limitation: GH and IGF-1 are surrogate outcomes for the proposed benefits.[21]
How certainty is assessed · Study reviews and review coverage